Hydroxychloroquine and Antimalarials for Lupus

Hydroxychloroquine and Antimalarials — scientific infographic poster

Table of Contents

  1. What Hydroxychloroquine Is and Why It Matters
  2. How It Actually Works: TLR7/9 and Lysosomal Alkalization
  3. The Survival Benefit: LUMINA and the Canadian Study
  4. Fewer Flares, Lower Damage Scores
  5. Blood Clot Reduction and Antiphospholipid Syndrome
  6. Lipid, Glucose, and Cardiovascular Perks
  7. The Pregnancy-Safe Anchor Drug
  8. Dosing: The 5 mg/kg Rule
  9. Blood Level Monitoring
  10. Retinal Toxicity Screening
  11. Other Side Effects, Including Skin Hyperpigmentation
  12. Drug Interactions
  13. Quinacrine as an Add-On for Refractory Skin Disease
  14. Chloroquine: The Older Cousin
  15. Practical Points About Taking It
  16. Key Research Papers
  17. Connections
  18. Featured Videos

What Hydroxychloroquine Is and Why It Matters

Hydroxychloroquine — usually abbreviated HCQ — is the single most important drug in lupus. Every major guideline (ACR, EULAR, the British Society for Rheumatology) says the same thing: every lupus patient who can tolerate it should be on it, for life. It is the "anchor drug," the one kept through remission, through pregnancy, through every other medication change.

It started its career in the 1940s as an antimalarial for American soldiers in the Pacific. Dermatologists noticed that troops taking it had unexpectedly clear skin — their rashes improved. By the 1950s it was being tested in lupus and rheumatoid arthritis, and by the 1990s a landmark trial had proven that stopping it triggers flares. In lupus, HCQ is not optional background noise. It is the drug keeping the disease quiet.

And yet patients constantly ask: "If I feel fine, can I stop it?" The research answer is almost always no — and this article explains why, in detail, with the actual studies that settled the question.

How It Actually Works: TLR7/9 and Lysosomal Alkalization

Hydroxychloroquine is a weak base. After a tablet is swallowed, the molecule drifts through the bloodstream and gets concentrated inside a tiny compartment in every cell called the lysosome — the cell's acidic recycling bin. Normally the lysosome sits at pH 4.5. HCQ soaks up protons and nudges that pH up toward 6. That sounds trivial. It isn't.

Two immune sensors live inside those acidified compartments: Toll-like receptor 7 (TLR7) and Toll-like receptor 9 (TLR9). Their job is to detect viral RNA and DNA. In lupus, they misfire — they bind the patient's own nucleic acids (leaking out of dying cells), mistake them for a virus, and trigger the type I interferon cascade that drives most of the disease. HCQ raises lysosomal pH just enough that TLR7 and TLR9 can no longer engage their ligands properly. The false alarm quiets down. Interferon production drops. B cells stop producing as many autoantibodies.

HCQ also interferes with antigen processing (lysosomes are where your cells chop up proteins for MHC II presentation), dampens cytokine production by macrophages, and stabilizes lysosomal membranes so the enzymes that cause tissue damage stay contained. The net effect is a gentle, broad immune recalibration — not immunosuppression in the classic sense. Patients on HCQ do not get more infections.

The Survival Benefit: LUMINA and the Canadian Study

The single most important fact about HCQ is this: it keeps lupus patients alive longer. Two studies nailed this down.

The Canadian Hydroxychloroquine Study Group trial (1991, published in NEJM) was the first randomized, placebo-controlled withdrawal trial. Forty-seven clinically stable lupus patients on HCQ were randomized either to continue the drug (25) or to switch to placebo (22) for 24 weeks. Over those six months, patients on placebo were 2.5 times as likely to flare as those who stayed on HCQ (16 of 22 vs 9 of 25). Long-term follow-up showed the placebo group had higher damage accrual years later.

The LUMINA cohort (LUpus in MInorities: NAture vs. nurture) — a multi-ethnic U.S. study led by Graciela Alarcón — went further. In a case-control analysis of 608 Hispanic, African-American, and Caucasian lupus patients (61 of whom had died), LUMINA found that HCQ use was associated with reduced mortality, with an odds ratio of 0.13 unadjusted and 0.32 after adjusting with a propensity score for the factors that drive treatment decisions (patients with milder disease are more likely to be prescribed HCQ). Translated: HCQ use was linked to markedly lower odds of death, and the protective effect held after that adjustment. No other lupus drug has shown a comparable survival signal in observational data.

This is the evidence base behind "never stop hydroxychloroquine." Flare risk, organ damage, cardiovascular events, thrombosis, and all-cause mortality all move in the right direction when HCQ is on board.

Fewer Flares, Lower Damage Scores

Beyond survival, HCQ measurably reduces lupus flare frequency. Pooled data suggest flare rates drop by roughly 50% on continuous HCQ versus off it. Organ damage — measured by the SLICC/ACR Damage Index, which tracks irreversible changes like kidney scarring, avascular necrosis, cataracts, and stroke — accumulates more slowly on HCQ. Patients started on it early in their disease course have better long-term outcomes than those started years in.

This is why rheumatologists frequently prescribe HCQ the same day a lupus diagnosis is made, even before a full workup is complete, and even when symptoms are mild. Starting early pays dividends for decades.

Blood Clot Reduction and Antiphospholipid Syndrome

Lupus patients have a higher baseline risk of blood clots — deep vein thrombosis, pulmonary embolism, stroke, and pregnancy loss — especially those with antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta-2-glycoprotein I). HCQ cuts this risk. Multiple cohort studies have shown lower thrombotic event rates on HCQ, with effect sizes in the range of a 30–70% reduction.

The mechanism is several-fold: HCQ inhibits platelet aggregation directly, reduces antiphospholipid antibody binding to cell membranes, and reverses some of the pro-coagulant surface changes that antiphospholipid antibodies cause. For a patient with lupus plus antiphospholipid antibodies, rheumatologists treat HCQ as a core part of the regimen — it is doing work anticoagulants cannot do.

Lipid, Glucose, and Cardiovascular Perks

HCQ has a cluster of metabolic side benefits that surprise most patients:

None of these is a reason to start HCQ on its own — but they are part of what is lost when it is stopped because lupus "feels fine."

The Pregnancy-Safe Anchor Drug

HCQ is one of the very few lupus medications that is explicitly recommended to continue during pregnancy. Stopping it in pregnancy increases flare risk, which is bad for both mother and baby. Continuing it:

HCQ crosses the placenta and is also secreted in breast milk at low levels, but decades of data show no birth defects, no growth restriction, and no developmental harm. Both the American College of Rheumatology and EULAR strongly recommend continuation throughout pregnancy and breastfeeding. Guidelines favour continuing HCQ when pregnancy is planned, and women with lupus who are not on it are commonly started on it before conception.

Dosing: The 5 mg/kg Rule

The old dosing instruction was 6.5 mg/kg of ideal body weight, up to 400 mg daily. That dose is now considered too high. In 2016, the American Academy of Ophthalmology (AAO) revised its guidelines in light of data showing that retinal toxicity risk rises sharply above 5 mg/kg of real body weight per day.

Current consensus dosing:

A 400 mg/day prescription is above the 5 mg/kg limit for anyone who weighs less than 80 kg (176 lb). Older prescriptions sometimes lag the updated guidelines.

Taking HCQ with food reduces nausea, which is the main reason patients abandon the drug in the first month. Many people take a single evening dose with dinner.

Blood Level Monitoring

HCQ has a long half-life (about 40 days), so steady-state blood levels take three to six months to reach. A growing number of rheumatologists now order HCQ whole-blood levels to do two things:

  1. Confirm adherence. A level under about 200 ng/mL suggests the patient is missing doses. Nonadherence is the most common reason for "HCQ failure."
  2. Look at the level against flare risk. In the 2013 French PLUS trial (573 patients), active lupus was less common at higher whole-blood HCQ levels, and the trial targeted a level of at least 1,000 ng/mL (the mean level was 918 ng/mL). Raising the dose to reach that target did not reduce flares over 7 months (25% vs 27.6%), although patients who stayed at the target tended to have fewer flares than those with low levels (20.5% vs 35.1%, not statistically significant).

Commercial laboratories offer HCQ blood level testing; it is a simple blood draw, usually covered by insurance when ordered by a rheumatologist. A low level despite faithful dosing may be an absorption issue (antacids, sucralfate, and kaolin-pectin reduce HCQ absorption) rather than a dosing failure. If levels are high, a small dose reduction can lower eye toxicity risk without losing efficacy.

Retinal Toxicity Screening

This is the side effect patients fear most, and fair enough — long-term HCQ can, in a minority, damage the retina in a pattern called bull's-eye maculopathy. Once established, the damage does not reverse. But modern screening catches it so early that visible vision loss has become rare.

The AAO 2016 screening schedule:

Risk factors that warrant earlier annual screening: dose above 5 mg/kg/day, kidney disease (HCQ is renally cleared), concurrent tamoxifen use, or pre-existing macular disease.

The screening test is not a standard eye exam. Under the 2016 AAO recommendations it includes:

The request that matches the guideline is: "hydroxychloroquine screening per the 2016 AAO guidelines — OCT, 10-2 visual field, and fundus autofluorescence." A plain vision check is not a valid screen under those guidelines. Most academic and large private ophthalmology practices have the equipment.

At the currently recommended dose (≤5 mg/kg/day), retinal toxicity risk is under 1% at five years, about 2% at ten years, and rises to 20% only after 20+ years of use. If screening catches it early and HCQ is stopped, progression after stopping is minimal.

Other Side Effects, Including Skin Hyperpigmentation

Beyond the retina, HCQ is remarkably well tolerated. The most common issues:

Drug Interactions

HCQ has relatively few clinically important interactions, but the ones that exist matter:

Quinacrine as an Add-On for Refractory Skin Disease

Quinacrine (mepacrine) is the forgotten third antimalarial. It was used extensively during WWII as a malaria prophylactic. It is not manufactured commercially in the United States any more but is readily available from compounding pharmacies for around $50–150/month out of pocket.

Quinacrine is particularly useful for cutaneous lupus that has not responded to HCQ alone. Adding quinacrine 100 mg/day to standard HCQ can clear persistent skin lesions in a substantial fraction of patients. Crucially, quinacrine does not cause retinal toxicity — it does not bind to the retinal pigment epithelium the way HCQ and chloroquine do. So it can be layered on without increasing eye screening burden.

Its main side effect is a yellow skin discoloration (from the drug itself deposited in skin) that can be dramatic and is why some patients decline it. The yellow fades over weeks to months after stopping. Less commonly, quinacrine can cause hematologic side effects (aplastic anemia is rare but reported), so complete blood count (CBC) monitoring is standard for the first few months. It is not used in pregnancy.

For cutaneous lupus not adequately controlled on HCQ and photoprotection, compounded quinacrine is the add-on described above. See also the cutaneous lupus article.

Chloroquine: The Older Cousin

Chloroquine was the original antimalarial used in lupus, before HCQ (a hydroxylated derivative) was shown to have a better safety profile. Chloroquine is more potent mg-for-mg but carries a substantially higher retinal toxicity risk and more gastrointestinal (GI) side effects. It is rarely prescribed for lupus in the United States today — HCQ has essentially replaced it — but it remains common in parts of Latin America, Asia, and Europe. Chloroquine for malaria prophylaxis on top of HCQ for lupus doubles up two closely related antimalarials; other malaria prophylaxis options exist.

Practical Points About Taking It

Key Research Papers

  1. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150–154. — doi:10.1056/NEJM199101173240303
  2. Alarcón GS, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–1172. — PubMed PMID: 17389655
  3. Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016. — doi:10.1016/j.ophtha.2016.01.058
  4. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014. — doi:10.1001/jamaophthalmol.2014.3459
  5. Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019. — doi:10.1136/annrheumdis-2019-215089
  6. Ruiz-Irastorza G, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006. — doi:10.1177/0961203306071872
  7. Costedoat-Chalumeau N, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013;72(11):1786–1792. — doi:10.1136/annrheumdis-2012-202322
  8. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011. — doi:10.1007/s11926-010-0141-y

PubMed Topic Searches

For further reading, these PubMed topic searches surface current peer-reviewed work on hydroxychloroquine pharmacology, monitoring, and use in lupus:

  1. PubMed: Hydroxychloroquine and lupus survival
  2. PubMed: Hydroxychloroquine mechanism: TLR7 and TLR9 inhibition
  3. PubMed: Hydroxychloroquine retinal toxicity and screening
  4. PubMed: Hydroxychloroquine blood level monitoring
  5. PubMed: Hydroxychloroquine in lupus pregnancy
  6. PubMed: Hydroxychloroquine and antiphospholipid-related thrombosis
  7. PubMed: Quinacrine for cutaneous lupus
  8. PubMed: Hydroxychloroquine effects on lipids and glucose

Back to Table of Contents

Connections

Back to Table of Contents